Table 1.
Characteristics of analyzed PTC cohort with BRAF, RAS and TERTp mutational status, and associations between clinico-histopathological and molecular features.
| Clinical/Histopathological Features | Total | NM-PTC | RAS(+) | BRAF(+)RAS(+) | BRAF(+)TERTp(−) | BRAF(+)TERTp(+) | Comparison Between the 5 Mutational Subgroups p-Value | BRAF(+)TERTp(+) vs. BRAF(+)TERTp(−) p-Value |
|---|---|---|---|---|---|---|---|---|
| No. 54 | No. 22 | No. 5 | No. 1 | No. 18 | No. 8 | |||
| Sex | 0.94 | 0.66 | ||||||
| Male | 21 (38.9%) | 9 (40.9%) | 2 (40.0%) | 0 (0.0%) | 6 (33.3%) | 4 (50.0%) | ||
| Female | 33 (61.1%) | 13 (59.1%) | 3 (60.0%) | 1 (100.0%) | 12 (66.7%) | 4 (50.0%) | ||
| Age at diagnosis | 0.005 | 0.14 | ||||||
| 48.5 (31.2–68.2) | 33.0 (21.0–46.8) | 49.0 (49.0–57.0) | 17.0 (17.0–17.0) | 55.0 (42.5–72.2) | 72.5 (56.5–77.2) | |||
| Classification according to the age at diagnosis | 0.0005 | 0.28 | ||||||
| <45 years | 19 (35.2%) | 14 (63.6%) | 0 (0.0%) | 1 (100.0%) | 4 (22.2%) | 0 (0.0%) | ||
| >45 years | 35 (64.8%) | 8 (36.4%) | 5 (100.0%) | 0 (0.0%) | 14 (77.8%) | 8 (100.0%) | ||
| Histopathological PTC classification | 0.15 | 1.00 | ||||||
| Classical variant | 46 (85.2%) | 17 (77.3%) | 3 (60.0%) | 1 (100.0%) | 17 (94.4%) | 8 (100.0%) | ||
| Follicular variant | 8 (14.8%) | 5 (22.7%) | 2 (40.0%) | 0 (0.0%) | 1 (5.6%) | 0 (0.0%) | ||
| Tumor diameter [mm] | 0.014 | 0.0008 | ||||||
| 24.0 (15.0–30.0) | 21.0 (13.5–30.0) | 30.0 (12.0–35.0) | 31.0 (31.0–31.0) | 18.0 (13.5–25.0) | 40.0 (29.5–61.2) | |||
| Multifocality | 0.59 | 0.40 | ||||||
| No | 26 (48.1%) | 9 (40.9%) | 2 (40.0%) | 1 (100.0%) | 11 (61.1%) | 3 (37.5%) | ||
| Yes | 28 (51.9%) | 13 (59.1%) | 3 (60.0%) | 0 (0.0%) | 7 (38.9%) | 5 (62.5%) | ||
| Invasion of the tumor capsule | 0.17 | 0.22 | ||||||
| No | 25 (46.3%) | 8 (36.4%) | 4 (80.0%) | 1 (100.0%) | 10 (55.6%) | 2 (25.0%) | ||
| Yes | 29 (53.7%) | 14 (63.6%) | 1 (20.0%) | 0 (0.0%) | 8 (44.4%) | 6 (75.0%) | ||
| Invasion of the surrounding tissues | 0.041 | 0.014 | ||||||
| No | 41 (75.9%) | 16 (72.7%) | 5 (100.0%) | 1 (100.0%) | 16 (88.9%) | 3 (37.5%) | ||
| Yes | 13 (24.1%) | 6 (27.3%) | 0 (0.0%) | 0 (0.0%) | 2 (11.1%) | 5 (62.5%) | ||
| Angioinvasion | 0.27 | 0.31 | ||||||
| No | 48 (88.9%) | 18 (81.8%) | 4 (80.0%) | 1 (100.0%) | 18 (100.0%) | 7 (87.5%) | ||
| Yes | 6 (11.1%) | 4 (18.2%) | 1 (20.0%) | 0 (0.0%) | 0 (0.0%) | 1 (12.5%) | ||
| pN1a | 0.25 | 0.20 | ||||||
| No | 22 (40.7%) | 7 (31.8%) | 2 (40.0%) | 0 (0.0%) | 11 (61.1%) | 2 (25.0%) | ||
| Yes | 32 (59.3%) | 15 (68.2%) | 3 (60.0%) | 1 (100.0%) | 7 (38.9%) | 6 (75.0%) | ||
| pN1b | 0.095 | 0.038 | ||||||
| No | 27 (50.0%) | 9 (40.9%) | 3 (60.0%) | 0 (0.0%) | 13 (72.2%) | 2 (25.0%) | ||
| Yes | 27 (50.0%) | 13 (59.1%) | 2 (40.0%) | 1 (100.0%) | 5 (27.8%) | 6 (75.0%) | ||
| Locally persistent disease after the 1st surgery | 0.012 | 0.005 | ||||||
| No | 47 (87.0%) | 19 (86.4%) | 5 (100.0%) | 1 (100.0%) | 18 (100.0%) | 4 (50.0%) | ||
| Yes | 7 (13.0%) | 3 (13.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (50.0%) | ||
| Local recurrence | 0.01 | 0.086 | ||||||
| No | 49 (90.7%) | 21 (95.5%) | 4 (80.0%) | 0 (0.0%) | 18 (100.0%) | 6 (75.0%) | ||
| Yes | 5 (9.3%) | 1 (4.5%) | 1 (20.0%) | 1 (100.0%) | 0 (0.0%) | 2 (25.0%) | ||
| Distant metastases | 0.015 | 0.008 | ||||||
| Yes | 24 (44.4%) | 12 (54.5%) | 3 (60.0%) | 0 (0.0%) | 3 (16.7%) | 6 (75.0%) | ||
| No | 30 (55.6%) | 10 (45.5%) | 2 (40.0%) | 1 (100.0%) | 15 (83.3%) | 2 (25.0%) | ||
| Follow up | 95.9 (78.6–112.7) | 95.9 (75.5–110.2) | 104.6 (89.6–105.4) | 84.4 (84.4–84.4) | 101.7 (80.8–119.8) | 94.4 (87.1–100.7) | 0.86 | 0.50 |
| [months] | ||||||||